Lineage Cell Therapeutics reported second-quarter 2026 financial results and provided updates on its cell-therapy pipeline. The company ended the quarter with $50.8 million in cash and marketable securities, extending its expected runway into the third quarter of 2028. Revenue fell to $1.1 million from $2.8 million a year earlier, while net income reached $1.5 million, or $0.01 per basic share, primarily due to a non-cash warrant-liability gain. Preclinical programs in corneal disease, Type 1 diabetes, and hearing loss advanced, and the OPC1 DOSED study treated two chronic spinal-cord-injury patients without unexpected safety issues. OpRegen remains eligible for up to $615 million in development and commercial milestones plus tiered double-digit royalties under the Roche and Genentech agreement.
Lineage Cell Therapeutics IncReports Q2 2026 earnings with cash runway extended into 2028 and pipeline progress.
Roche Holding AG